Syngene International Limited announced its audited financial results for FY26 and Q4 performance on April 29, 2026, revealing mixed operational performance with revenue growth offset by significant margin compression and profitability decline.

Q4 FY26 Performance Overview

The company's Q4 performance showed challenging operational metrics with revenue from operations growing 2% year-on-year to ₹1,037 crores. However, operating EBITDA declined 12% to ₹303 crores, resulting in margin compression to 29% from 34% in the corresponding quarter last year.

Annual Financial Performance FY26

For the full year ended March 31, 2026, Syngene delivered revenue growth of 3% to ₹3,739 crores, but profitability declined significantly. Operating EBITDA margin compressed to 25% from 29% in the previous year, while profit after tax before exceptional items fell 20% to ₹380 crores.

Leadership Statements and Strategic Outlook

Executive Chairperson Kiran Mazumdar-Shaw highlighted the company's resilient business model, stating that Syngene's diversified end-to-end platform from discovery to manufacturing provides strategic agility in navigating current market realities. The company continues investing in AI and digital capabilities to enhance client value creation.

Managing Director and CEO Peter Bains noted that performance aligned with revised full-year guidance, with underlying business showing steady momentum despite impact from a single large-molecule biologics client. CFO Deepak Jain attributed the margin compression to the biologics customer impact and additional operating costs from bringing the new biologics manufacturing facility online.

Key Board and Management Changes

The company announced significant leadership transitions effective from various dates in 2026. Kiran Mazumdar-Shaw transitioned from Non-Executive to Executive Chairperson for a five-year term starting April 1, 2026. Siddharth Mittal will join as Managing Director and CEO from July 1, 2026, succeeding Peter Bains.

Dividend Declaration and Corporate Actions

The board recommended a final dividend of ₹1.25 per equity share of ₹10.00 face value for FY26, subject to shareholder approval. The company also approved the appointment of S. R. Batliboi & Associates LLP as statutory auditors for a five-year term from 2026-2031, and scheduled the 33rd Annual General Meeting for July 29, 2026.

Business Highlights and Strategic Investments

During the quarter, Syngene expanded its Antibody-Drug Conjugate capabilities by commencing operations at its ADC discovery laboratory equipped for highly potent compounds. The company completed 14 client and regulatory audits in Q4, bringing the full-year total to 85, and obtained GCP-NABL accreditation. Syngene also earned recognition in the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies globally.

Syngene International announced key board appointments following its board meeting held on April 29, 2026. The biotechnology services company approved the appointment of two new independent directors and the reappointment of an existing director, subject to shareholder approval.

Board Appointments and Reappointments

Based on recommendations from the Nomination & Remuneration Committee, the board approved three significant directorial changes:

The 33rd Annual General Meeting is scheduled to be held on July 29, 2026.

New Director Profiles

Mr. Vijaya Chandru

Vijaya Chandru brings over 25 years of deep-tech innovation experience as a leading academic-entrepreneur. He holds a PhD in Operations Research from Massachusetts Institute of Technology and specializes in decision sciences, optimization, geometry, logic, and computational biology.

His entrepreneurial achievements include co-founding multiple technology companies:

• Strand Life Sciences (2000)
• PicoPeta Simputers (2001)
• Yantri Labs Inc. (2018)
• CRISPRBITS

Chandru serves on faculty at prestigious institutions including National Centre for Biological Sciences, Indian Institute of Science, and Harvard T.H. Chan School of Public Health. In 2024, the American Association for the Advancement of Science elected him Fellow for contributions to theoretical computer science, computational biology, and technology for social good. The World Economic Forum named him a Technology Pioneer in 2006.

Mr. Arun Chandavarkar

Arun Chandavarkar retired as CEO & Joint Managing Director of Biocon Limited on November 30, 2019, after a distinguished 29-year career. During his tenure, he played an instrumental role in transforming Biocon from an enzymes business into a globally recognized biopharma company.

His key contributions at Biocon included:

• Leading the company's 2004 IPO
• Establishing biologics partnerships
• Overseeing major R&D and infrastructure investments
• Managing the divestment of the enzymes business
• Implementing organizational restructuring initiatives

Chandavarkar holds a B.Tech. in Chemical Engineering from Indian Institute of Technology Bombay and a PhD in Chemical Engineering from Massachusetts Institute of Technology. He previously served as Chairperson of the biotechnology committee at Confederation of Indian Industry and currently serves as a non-executive director at Biocon Biologics and an independent director at Mynvax Private Limited.

Continuing Leadership

Ms. Vinita Bali

Vinita Bali's reappointment extends her valuable contribution to Syngene's board. She brings extensive global business leadership experience, having served as Chief Executive Officer & MD of Britannia Industries Ltd. from 2005 to 2014. Her international experience includes senior roles at The Coca-Cola Company and Cadbury Schweppes Plc across multiple countries including the UK, Nigeria, South Africa, USA, and Chile.

Currently, she serves as Non-Executive Director on global boards of SATS Ltd and Cognizant Technology Solutions, and in India, she serves on the board of Bajaj Auto Limited. At Syngene, she actively participates as a member of the Nomination & Remuneration Committee, Audit Committee, and Corporate Social Responsibility Committee.

Regulatory Compliance

The company confirmed compliance with SEBI regulations, stating that all three directors are not debarred from holding director positions by SEBI or any other authority. The appointments align with SEBI letter dated June 14, 2018, and NSE Circular dated June 20, 2018, reference number NSE/CML/2018/24.

All appointments require shareholder approval and will be presented at the upcoming Annual General Meeting for formal ratification.